Synthetic peptide vaccine of B cell epitope based on TGF(transforming growth factor)-beta1 and application thereof

A synthetic peptide vaccine, TGF-technology, applied in the field of synthetic peptide vaccines, can solve problems such as inconvenient use, complicated preparation methods, poor application prospects, etc., and achieve the effect of inhibiting development

Inactive Publication Date: 2013-05-08
THE FIRST AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XIAN JIAOTONG UNIV
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, from the perspective of clinical application, the above methods all have outstanding shortcomings such as comp

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synthetic peptide vaccine of B cell epitope based on TGF(transforming growth factor)-beta1 and application thereof
  • Synthetic peptide vaccine of B cell epitope based on TGF(transforming growth factor)-beta1 and application thereof
  • Synthetic peptide vaccine of B cell epitope based on TGF(transforming growth factor)-beta1 and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0046] The present invention provides a synthetic peptide vaccine based on TGF-β1 B cell antigen epitope and its application. The antigenic epitope peptide is screened and coupled with a carrier protein to synthesize a TGF-β1 peptide vaccine, and mice are immunized by intraperitoneal injection. Repeat immunization and detect mouse serum antibody titer, CCl 4 Induced mouse model of liver fibrosis. HE and Masson staining were used to observe the pathological changes of liver tissue. Immunohistochemical staining in liver tissue. Alkaline hydrolysis was used to detect the content of hydroxyproline in the liver tissue of each group, to observe the fibrosis of the liver tissue of the mice in each group, and to compare the differences in the degree of liver fibrosis between the vaccine immunization group, the model group, and the KLH group. The present invention will be further described in detail below in conjunction with specific examples, which are explanations of the present in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a synthetic peptide vaccine of B cell epitope based on TGF(transforming growth factor)-beta1 and application thereof, inhibits auxo-action of the cell factor TGF-B1-BB during the development process of liver fibrosis so as to inhibit the development of liver fibrosis to a some extent by constructing two epitope peptides of AY25 and LS30, coupling carrier proteins to synthesize an TGF-beta1 peptide vaccine, immunizing an ICR mice by intraperitoneal injection to induce the same to generate an anti-TGF-beta1 antibody, and neutralizing the cell factor TGF-B1-BB over expressed during CCL4 induced hepatic fibrosis process.

Description

technical field [0001] The invention belongs to the technical field of prevention and treatment of liver fibrosis, and relates to a synthetic peptide vaccine based on TGF-β1 B cell antigen epitope and its application. Background technique [0002] Liver fibrosis is the pathological process necessary for a variety of chronic liver diseases to develop into cirrhosis, and is the most important factor determining the prognosis of chronic liver diseases. At present, most chronic liver diseases lack effective etiological treatment, and studies have confirmed that liver fibrosis can continue to progress after the cause of some liver diseases is removed, so the occurrence and development of liver fibrosis can be blocked or delayed to prevent the progression from liver cirrhosis to chronic liver disease One of the main ways of treatment. However, there are no effective anti-hepatic fibrosis drugs or measures at present. Exploring safe and effective anti-hepatic fibrosis measures is ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/495C07K16/24A61K39/385A61P1/16
Inventor 郝志明李爽樊小宝吕颐菲苏厚强蒋会平张倩楠郑晓燕
Owner THE FIRST AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XIAN JIAOTONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap